Ibogaine is a Schedule 9 Prohibited Substance in Australia under the Therapeutic Goods (Poisons Standard), making its manufacture, supply, possession, and use illegal except in very limited, approved research or compassionate-access contexts. Last verified: April 2026.

Current Legal Status

Under the Therapeutic Goods (Poisons Standard) — commonly known as the Poisons Standard — ibogaine is listed as a Schedule 9 (Prohibited Substance). Schedule 9 is the most restrictive classification in Australia's drug scheduling framework, reserved for substances with a high potential for abuse or harm and no currently accepted therapeutic use. Possession, supply, manufacture, or importation of Schedule 9 substances is prohibited except where specifically authorised by the Therapeutic Goods Administration (TGA) for approved research purposes.

It is important to distinguish ibogaine's status from that of other psychedelic substances recently rescheduled in Australia. In 2023, the TGA rescheduled psilocybin and MDMA from Schedule 9 to Schedule 8 (Controlled Drug), permitting their use in specific clinical settings under authorised psychiatrists. Ibogaine was not included in this rescheduling and remains at Schedule 9. No equivalent reclassification of ibogaine has been approved or announced by the TGA.

At the state and territory level, drug offences related to Schedule 9 substances carry serious criminal penalties. Charges and maximum sentences vary by jurisdiction — for example, under New South Wales's Drug Misuse and Trafficking Act 1985 and Victoria's Drugs, Poisons and Controlled Substances Act 1981 — but possession and supply of prohibited substances can result in significant fines and imprisonment.

Special Access Scheme (SAS) Category A

The TGA operates the Special Access Scheme (SAS), which provides a limited pathway for seriously ill patients to access unapproved therapeutic goods, including Schedule 9 substances, outside of registered clinical trials. Under SAS Category A, a medical practitioner can notify the TGA to supply an unapproved product — including a Schedule 9 substance — to a patient who is seriously ill with a life-threatening condition where no other suitable treatment is available.

This pathway is highly restricted and intended only for individual compassionate-access cases. It does not legalise ibogaine broadly, does not permit commercial treatment centres to operate, and requires the treating physician to take full clinical and legal responsibility. In practice, SAS Category A access to ibogaine is exceedingly rare. No ibogaine product is TGA-approved, meaning any access through this route involves significant regulatory complexity and clinical risk assessment by the authorising practitioner.

Important: The existence of the SAS Category A pathway does not mean ibogaine treatment is practically accessible in Australia. No licensed ibogaine treatment centres operate in Australia. Seeking ibogaine outside of an approved SAS or clinical trial framework carries serious legal and health risks.

Treatment Centers

There are no licensed ibogaine treatment centres operating in Australia. Because ibogaine remains a Schedule 9 Prohibited Substance, commercial or clinical administration of ibogaine outside of TGA-approved research or a valid SAS Category A authorisation is illegal. Any facility purporting to offer ibogaine treatment in Australia without specific TGA authorisation would be operating outside the law.

Some Australians travel abroad to access ibogaine-assisted therapy in jurisdictions where it is legal or unscheduled — most commonly Portugal, Mexico, the Netherlands, or South Africa. For a directory of internationally operating clinics, see our full clinic directory.

How People Access Ibogaine in Australia

The following reflects documented patterns of access and is presented factually. Nothing here constitutes a recommendation.

  • Medical travel: The most common route for Australians seeking ibogaine treatment is travelling to countries where it is legally administered, such as Portugal, Mexico, the Netherlands, or South Africa. Returning to Australia after receiving ibogaine treatment abroad is not itself a criminal offence, but importing ibogaine into Australia is prohibited.
  • SAS Category A: In exceptional circumstances, a medical practitioner treating a seriously ill patient may seek TGA notification under SAS Category A to access ibogaine as an unapproved therapeutic good. This is extremely rare and requires the physician to take on substantial clinical and regulatory obligations.
  • Approved research trials: Australian researchers can apply to the TGA and relevant ethics committees to conduct clinical trials involving Schedule 9 substances, including ibogaine. Participants in approved trials may legally receive ibogaine as part of the trial protocol. No large-scale ibogaine trials are currently publicly listed in Australia's clinical trials registry as of April 2026, though interest is growing.
  • Illicit sources: Some individuals obtain ibogaine or iboga-containing plant material (such as Tabernanthe iboga root bark) through unregulated channels. This carries serious legal risks under federal and state drug laws, as well as significant health risks due to no medical supervision or quality control.

Recent Legal Developments

The most significant recent development in Australian psychedelic policy was the TGA's February 2023 decision to reschedule psilocybin and MDMA from Schedule 9 to Schedule 8, making Australia the first country in the world to permit the clinical use of these substances in a regulated therapeutic setting. This took effect on 1 July 2023.

However, ibogaine was explicitly excluded from this rescheduling decision. The TGA's reasoning centred on the narrow cardiac safety margin of ibogaine, its association with fatal adverse events in uncontrolled settings, and the lack of robust Phase II/III clinical trial data comparable to what existed for psilocybin and MDMA at the time of the decision.

Since then, there has been growing advocacy within Australia's harm reduction and addiction medicine communities for further research into ibogaine, particularly given international evidence suggesting efficacy in treating opioid use disorder. Researchers at several Australian universities have expressed interest in pursuing ibogaine trials, and the topic has appeared in federal parliamentary discussions about expanding Australia's psychedelic medicine research agenda. However, no formal TGA rescheduling application for ibogaine has been publicly announced as of April 2026.

The TGA reviews the Poisons Standard periodically, and stakeholders may submit scheduling proposals. Any future rescheduling of ibogaine would require evidence of therapeutic benefit outweighing risk, along with appropriate clinical safeguards — particularly regarding cardiac monitoring.

Risks of Seeking Treatment in Australia

Because no legal ibogaine treatment framework exists in Australia, individuals who access ibogaine outside of approved channels face compounding risks:

  • Legal risk: Possession, supply, or importation of a Schedule 9 substance carries serious criminal penalties under both federal law (the Criminal Code Act 1995) and state/territory drug legislation. Penalties vary but can include substantial fines and imprisonment.
  • No quality control: Ibogaine obtained through illicit or grey-market sources has no guaranteed purity, concentration, or composition. Adulterated or mislabelled substances significantly increase the risk of overdose or cardiac events. Ibogaine has a narrow therapeutic window and known QT-prolongation risk.
  • No medical supervision: Ibogaine carries a real risk of life-threatening cardiac arrhythmia, particularly in individuals with underlying heart conditions or those concurrently using other substances. Safe administration requires ECG screening, cardiac monitoring throughout the session, and emergency medical capability — none of which are available in underground settings.
  • No legal recourse: Individuals harmed while accessing ibogaine in an illicit context have limited ability to seek legal remedy against providers, and may face legal scrutiny themselves if harm occurs and authorities become involved.
  • Provider quality: Unregulated underground providers have no mandatory training, certification, or accountability. The quality of screening, dosing, and harm reduction practices varies enormously.

Cardiac safety warning: Ibogaine is associated with QT interval prolongation and has caused deaths in otherwise healthy individuals. Any administration without prior cardiac screening (ECG, electrolyte panel) and continuous monitoring during the session is medically dangerous, regardless of legal context.

Frequently Asked Questions

No. Ibogaine is a Schedule 9 Prohibited Substance under the Therapeutic Goods (Poisons Standard). This is the most restrictive drug classification in Australia. Possession, supply, manufacture, and importation are prohibited except in narrow, TGA-authorised research or compassionate-access circumstances.
Partially. In 2023, the TGA rescheduled psilocybin and MDMA from Schedule 9 to Schedule 8, allowing their use in specific clinical settings under authorised psychiatrists from 1 July 2023. Ibogaine was not included in this change and remains Schedule 9. The TGA cited ibogaine's cardiac safety profile and limited clinical trial evidence as reasons for exclusion.
The TGA's Special Access Scheme (SAS) Category A allows a medical practitioner to notify the TGA and supply an unapproved product, including Schedule 9 substances, to a seriously ill patient with a life-threatening condition when no other suitable treatment exists. In theory, this pathway could be used for ibogaine in exceptional cases. In practice, it is extremely rare: no ibogaine product is TGA-approved, the prescribing physician takes on full legal and clinical responsibility, and the logistical and regulatory hurdles are substantial. This is not a routine access pathway.
No licensed ibogaine treatment centres operate in Australia. Administering ibogaine commercially or clinically without TGA authorisation is illegal. Australians who seek ibogaine-assisted therapy typically travel to countries where it is legally offered, such as Portugal, Mexico, the Netherlands, or South Africa. See our clinic directory for internationally operating facilities.
The Poisons Standard's Schedule 9 listing covers ibogaine as a substance. Plant material such as Tabernanthe iboga root bark that contains ibogaine as its principal active alkaloid may also be captured under the scheduling, and importation of such material is likely to be intercepted by the Australian Border Force. The legal position on iboga-containing plant material can be complex and may engage both the Poisons Standard and the Criminal Code Act 1995. You should seek advice from a qualified Australian lawyer before attempting to import any iboga-containing product.
No. Ibogaine is a Class C controlled substance in New Zealand under the Misuse of Drugs Act 1975. No legal ibogaine treatment centres operate in New Zealand. New Zealand is not a viable destination for Australians seeking legal ibogaine-assisted therapy.
It is possible but currently speculative. The TGA reviews the Poisons Standard on a rolling basis, and any party may submit a scheduling proposal. Growing international research into ibogaine for opioid use disorder — including studies in the United States, Canada, and Europe — may eventually generate sufficient clinical evidence to support a rescheduling application in Australia. The primary obstacle is ibogaine's cardiac safety profile, which would require any future clinical framework to include mandatory pre-treatment cardiac screening and monitoring protocols. No formal rescheduling application has been publicly announced as of April 2026.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.